Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a pioneering biopharmaceutical company headquartered in Vancouver, British Columbia. Focused on neurology, Xenon leverages its proprietary discovery platform, termed 'extreme genetics', to develop innovative medications. The company’s approach involves studying families with severe phenotypes to identify single-gene defects, which offer insights into human biology and serve as potential drug targets.
Xenon’s development pipeline targets a range of neurological disorders, particularly epilepsy and depression. The flagship product, XEN1101, is a potent, selective potassium channel opener currently in various phases of clinical trials for epilepsy and major depressive disorder (MDD). Xenon has ongoing Phase 3 trials for XEN1101 in focal onset seizures (X-TOLE2, X-TOLE3) and primary generalized tonic-clonic seizures (X-ACKT). The drug has shown promising efficacy in reducing seizures and improving quality of life in long-term extension studies.
Additionally, Xenon is exploring XEN1101's potential in treating MDD, with a Phase 3 program expected to begin in 2024. Recent interim data from the X-NOVA Phase 2 trial revealed significant improvements in depression symptoms, supporting further development for this indication. Xenon’s pre-clinical work includes investigations into Nav1.1 and Nav1.7 potentiators for various neurological conditions.
Key developments include a partnership with Neurocrine Biosciences to develop XEN901 (NBI-921352) for epilepsy. Xenon's financial stability, robust clinical pipeline, and strategic collaborations position it for continued growth and innovation in neurology-focused therapeutics.
Recent Achievements:
- Strong presence at AES 2023 with multiple presentations on XEN1101
- Presented new data from the Phase 2b X-TOLE trial demonstrating significant seizure freedom rates
- Expanded open-label extension study collecting over 500 patient years of data
- Announced positive topline results from X-NOVA Phase 2 trial for MDD
- Ongoing collaboration with Icahn School of Medicine for additional MDD studies
For more updates and detailed information, visit the official website.
Xenon Pharmaceuticals (Nasdaq:XENE) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 10-13, 2024, in Miami, FL.
Key executives, Ian Mortimer, President and CEO, and Chris Von Seggern, Chief Commercial Officer, will present during a fireside chat on June 12, at 4:00 pm ET. The presentation will be webcast live and available for replay on Xenon's investor relations webpage.
Xenon focuses on developing innovative treatments for neurological and psychiatric disorders, with a product pipeline addressing unmet medical needs such as epilepsy and depression.
Xenon Pharmaceuticals has presented Phase 2 clinical data for azetukalner (XEN1101) in major depressive disorder (MDD) at the ASCP 2024 Annual Meeting.
Key findings include a meaningful reduction in depression and early onset of action, with a significant reduction in anhedonia. Though a 3.04 MADRS score difference between placebo and 20 mg azetukalner was observed, it was not statistically significant (P=0.135). Significant differences were noted in HAM-D17 (P=0.042) and SHAPS scores (P=0.046).
Azetukalner was well tolerated with no serious adverse events reported. Common TEAEs included dizziness (17.9%), somnolence (10.7%), headache (8.9%), and disturbance in attention (8.9%). Discontinuation rates were low.
The company aims to initiate Phase 3 trials in late 2024.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) reported financial results for Q1 2024 and provided a corporate update. The company received approval for the use of 'azetukalner' as the nonproprietary name for XEN1101. Progress continues in the epilepsy program, with Phase 3 expected to start in MDD in the second half of 2024. Financially, Xenon has cash to fund operations into 2027.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the BofA Securities Health Care Conference 2024. The presentation will take place on May 15, 2024, in Las Vegas, NV, featuring the company's President, CEO, and CFO. The webcast will be available on the company's website for replay. Xenon is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for neurological and psychiatric disorders, such as epilepsy and depression.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 2024 RBC Capital Markets Global Healthcare Conference. The event will take place on May 14-15, 2024, in New York, NY. Presenters include Ian Mortimer, President and CEO, and Sherry Aulin, CFO. The company focuses on neuroscience, aiming to develop therapeutics for neurological and psychiatric disorders. Xenon's live webcast will be available on their website for replay.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its first quarter 2024 financial results on May 9, 2024. The company focuses on neuroscience and aims to develop innovative therapeutics for neurological and psychiatric disorders. Xenon encourages participants to pre-register for the conference call/webcast to discuss the results. The company is committed to addressing high unmet medical needs in areas such as epilepsy and depression.
FAQ
What is the current stock price of Xenon Pharmaceuticals (XENE)?
What is the market cap of Xenon Pharmaceuticals (XENE)?
What does Xenon Pharmaceuticals specialize in?
What is the focus of Xenon’s proprietary discovery platform?
What is XEN1101?
What are the recent achievements of Xenon Pharmaceuticals?
Who are Xenon’s strategic partners?
What are Xenon’s key products in the pipeline?
What is the status of the XEN1101 epilepsy trials?
How can I contact Xenon Pharmaceuticals for investor information?
Where is Xenon Pharmaceuticals headquartered?
What is the significance of Xenon’s pre-clinical work?
